We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.34%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
+$71.8M
Cap. Flow
-$218M
Cap. Flow %
-1.26%
Top 10 Hldgs %
90.2%
Holding
115
New
7
Increased
18
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$27.7M
2
ABCL icon
AbCellera Biologics
ABCL
+$26.2M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.1M
4
DNLI icon
Denali Therapeutics
DNLI
+$21.2M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$12.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$63.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$55.9M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$48.1M
4
IMGN
Immunogen Inc
IMGN
+$28.7M
5
ANAB icon
AnaptysBio
ANAB
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.2%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SERA icon
76
Sera Prognostics
SERA
$80.7M
$2.82M 0.02%
1,515,342
-262,093
-15% -$626K
PCVX icon
77
Vaxcyte
PCVX
$7.62B
$2.49M 0.01%
48,885
– –
XNCR icon
78
Xencor
XNCR
$1.45B
$2.48M 0.01%
123,127
– –
KALA icon
79
KALA BIO
KALA
$11.7M
$2.37M 0.01%
5,332
+3,008
+129% +$1.97M
ACHL
80
DELISTED
Achilles Therapeutics
ACHL
$2.33M 0.01%
2,557,149
– –
IPSC icon
81
Century Therapeutics
IPSC
$364M
$2.3M 0.01%
1,149,340
– –
AFMD
82
DELISTED
Affimed
AFMD
$2.13M 0.01%
444,864
-214,819
-33% -$1.18M
CATX icon
83
Perspective Therapeutics
CATX
$318M
$2.09M 0.01%
763,970
+532,041
+229% +$2.48M
TIL icon
84
Instil Bio
TIL
$49.2M
$2.01M 0.01%
235,220
-28,469
-11% -$287K
PMVP icon
85
PMV Pharmaceuticals
PMVP
$57.6M
$1.98M 0.01%
322,024
– –
ANAB icon
86
AnaptysBio
ANAB
$1.53B
$1.91M 0.01%
106,197
-669,727
-86% -$12.8M
PNT
87
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$1.67M 0.01%
249,968
-919,135
-79% -$7.64M
ITOS
88
DELISTED
iTeos Therapeutics
ITOS
$1.65M 0.01%
150,346
– –
CYPH
89
Cypherpunk Technologies Inc
CYPH
$63.1M
$1.62M 0.01%
1,172,175
– –
ALGS icon
90
Aligos Therapeutics
ALGS
$25.9M
$1.55M 0.01%
83,056
– –
MRSN
91
DELISTED
Mersana Therapeutics
MRSN
$1.38M 0.01%
43,445
– –
VOR icon
92
Vor Biopharma
VOR
$1.07B
$1.34M 0.01%
31,692
– –
NVTA
93
DELISTED
Invitae Corporation
NVTA
$1.07M 0.01%
1,764,546
-7,116,558
-80% -$7.4M
RNAM
94
DELISTED
Avidity Biosciences
RNAM
$1.06M 0.01%
166,347
-633,104
-79% -$5.45M
BCEL
95
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$922K 0.01%
3,532,760
– –
GTH
96
DELISTED
Genetron Holdings Limited ADS
GTH
$370K ﹤0.01%
151,769
– –
TARA icon
97
Protara Therapeutics
TARA
$213M
$333K ﹤0.01%
199,671
– –
FHTX icon
98
Foghorn Therapeutics
FHTX
$278M
$225K ﹤0.01%
45,027
– –
SRZNW icon
99
Surrozen Inc Warrant
SRZNW
$36.6K
$34.3K ﹤0.01%
833,333
– –
ALLO icon
100
Allogene Therapeutics
ALLO
$607M
– –
-1,576,901
Closed -$7.84M
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Baker Bros. Advisors held 115 positions worth $17.4B, up 0.42% from $17.3B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Baker Bros. Advisors's Q3 2023 filing shows 7 new, 18 increased, 11 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M. The largest sale was argenx, an estimated $63.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M.
  • Baker Bros. Advisors added most to Roivant Sciences in Q3 2023, an estimated $27.7M increase.
  • Baker Bros. Advisors's biggest Q3 2023 reduction was argenx, cutting an estimated $63.1M.
  • Baker Bros. Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $55.9M.
  • Baker Bros. Advisors's ten largest holdings make up 90% of its $17.4B portfolio in Q3 2023.
  • Baker Bros. Advisors opened 7 new positions and closed 14 in Q3 2023.
  • Baker Bros. Advisors's portfolio value rose 0.42% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.